Der Nachweis von isolierten Tumorzellen in Knochenmark und Blut von Patientinnen mit primärem Mammakarzinom - Standardisierte Methodik und klinische Relevanz

Zusammenfassung

Trotz wesentlicher Fortschritte in der systemischen Therapie des Mammkarzinoms und deutlicher Prognoseverbesserung sind Rezidive nach oft langer Latenzzeit für diese Erkrankung charakteristisch. Ausgangspunkt für eine Fernmetastasierung sind der Regel isolierte Tumorzellen, die bereits früh im Verlauf der Erkrankung hämatogen disseminieren. Der Nachweis dieser minimalen Tumorresiduen (minimal residual disease, MRD) ist mit konventionellen bildgebenden Verfahren nicht möglich. Der immunzytochemische Nachweis isolierter Tumorzellen im Knochenmark ist die am besten validierte Methode, um Tumorresiduen zu detektieren. Die daraus gewonnenen Informationen über Prävalenz und Phänotyp der Tumorzellen lassen Rückschlüsse auf Tumorbiologie und individuelle Prognose zu, und könnten in Zukunft in der adjuvanten Situation zu einer Optimierung der Therapie führen. Die Detektion von minimalen Tumorresiduen nach Abschluss der Primärtherapie könnte die Beantwortung der von Patientinnen häufig gestellten Frage nach dem individuellen Erfolg adjuvanter Therapien in Zukunft erleichtern und Grundlage für die Einleitung einer „sekundär-adjuvanten Therapie” im Rahmen der onkologischen Nachsorge sein.

Mammakarzinom - disseminierte Tumorzellen - isolierte Tumorzellen - Mikrometastasen - minimale Tumorresiduen - adjuvant - sekundär-adjuvant

Literatur

• 1 DeVita V TJ. Breast cancer therapy: exercising all our options.  N Eng J Med. 1989;  320 527-529
• 2 Rosner D, Lane W W. Predicting recurrence in axillary-node negative breast cancer patients.  Breast Cancer Res Treat. 1993;  25 127-139
• 3 Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich C R, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.  N Engl J Med. 2000;  342 525-533
• 4 Cote R J, Rosen P P, Lesser M L, Old L J, Osborne M P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.  J Clin Oncol. 1991;  9 1749-1756
• 5 Diel I J, Kaufmann M, Costa S D, Holle R, Minckwitz G von, Solomayer E F, Kaul S, Bastert G. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.  J Natl Cancer Inst. 1996;  88 1652-1658
• 6 Gebauer G, Fehm T, Merkle E, Beck E P, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up.  J Clin Oncol. 2001;  19 3669-3674
• 7 Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.  J Clin Oncol. 2001;  19 960-971
• 8 Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.  Br J Cancer. 1994;  69 566-571
• 9 Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up.  Breast Cancer Res Treat. 1998;  49 27-33
• 10 Mansi J L, Gogas H, Bliss J M, Gazet J C, Berger U, Coombes R C. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study.  Lancet. 1999;  354 197-202
• 11 Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer.  Clin Cancer Res. 2004;  10 2670-2674
• 12 Gangnus R, Langer S, Breit E, Pantel K, Speicher M R. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients.  Clin Cancer Res. 2004;  10 3457-3464
• 13 Klein C A, Blankenstein T J, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein N H, Riethmuller G. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.  Lancet. 2002;  360 683-689
• 14 Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein T J, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein C A. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression.  Proc Natl Acad Sci USA. 2003;  100 7737-7742
• 15 Bostick P J, Chatterjee S, Chi D D, Huynh K T, Giuliano A E, Cote R, Hoon D S. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.  J Clin Oncol. 1998;  16 2632-2640
• 16 Zippelius A, Kufer P, Honold G, Kollermann M W, Oberneder R, Schlimok G, Riethmuller G, Pantel K. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow.  J Clin Oncol. 1997;  15 2701-2708
• 17 Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou E S, Stathopoulos S, Georgoulias V, Mavroudis D. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.  J Clin Oncol. 2006;  24 3756-3762
• 18 Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.  Cancer. 2006;  107 885-892
• 19 Braun S, Pantel K. Prognostic significance of micrometastatic bone marrow involvement.  Breast Cancer Res Treat. 1998;  52 201-216
• 20 Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer.  J Hematother. 1994;  3 315-322
• 21 Borgen E, Naume B, Nesland J M, Nowels K W, Pavlak N, Ravkin I, Goldbard S. Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples.  Cytometry. 2001;  46 215-221
• 22 Borgen E, Beiske K, Trachsel S, Nesland J M, Kvalheim G, Herstad T K, Schlichting E, Qvist H, Naume B. Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase.  J Pathol. 1998;  185 427-434
• 23 Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki J R, Riethmuller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells.  J Natl Cancer Inst. 1993;  85 1419-1424
• 24 Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmuller G, Pantel K. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases.  Cancer Res. 1999;  59 241-248
• 25 Weckermann D, Muller P, Wawroschek F, Krawczak G, Riethmuller G, Schlimok G. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors.  J Clin Oncol. 1999;  17 3438-3443
• 26 Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen L W, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses.  Proc Natl Acad Sci USA. 2004;  101 9393-9398
• 27 Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann M W, Kollermann J, Speicher M R, Pantel K. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.  Proc Natl Acad Sci USA. 2002;  99 2246-2251
• 28 Braun S, Vogl F D, Naume B, Janni W, Osborne M P, Coombes R C, Schlimok G, Diel I J, Gerber B, Gebauer G, Pierga J Y, Marth C, Oruzio D, Wiedswang G, Solomayer E F, Kundt G, Strobl B, Fehm T, Wong G Y, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer.  N Engl J Med. 2005;  353 793-802
• 29 Diel I J, Solomayer E F, Costa S D, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.  N Engl J Med. 1998;  339 357-363
• 30 Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, Swierkot S, Warnecke H H, Schneider B, Koprowski H, et a. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies.  Proc Natl Acad Sci USA. 1987;  84 8672-8676
• 31 Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland J M, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.  J Clin Oncol. 2003;  21 3469-3478
• 32 Fields K K, Elfenbein G J, Trudeau W L, Perkins J B, Janssen W E, Moscinski L C. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.  J Clin Oncol. 1996;  14 1868-1876
• 33 Datta Y H, Adams P T, Drobyski W R, Ethier S P, Terry V H, Roth M S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction.  J Clin Oncol. 1994;  12 475-482
• 34 Vannucchi A M, Bosi A, Glinz S, Pacini P, Linari S, Saccardi R, Alterini R, Rigacci L, Guidi S, Lombardini L, Longo G, Mariani M P, Rossi-Ferrini P. Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA.  Br J Haematol. 1998;  103 610-617
• 35 Courtemanche D J, Worth A J, Coupland R W, MacFarlane J K. Detection of micrometastases from primary breast cancer.  Can J Surg. 1991;  34 15-19
• 36 Funke I, Fries S, Rolle M, Heiss M M, Untch M, Bohmert H, Schildberg F W, Jauch K W. Comparative analyses of bone marrow micrometastases in breast and gastric cancer.  Int J Cancer. 1996;  65 755-761
• 37 Molino A, Pelosi G, Turazza M, Sperotto L, Bonetti A, Nortilli R, Fattovich G, Alaimo C, Piubello Q, Pavanel F, Micciolo R, Cetto G L. Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis.  Breast Cancer Res Treat. 1997;  42 23-30
• 38 Porro G, Menard S, Tagliabue E, Orefice S, Salvadori B, Squicciarini P, Andreola S, Rilke F, Colnaghi M I. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients.  Cancer. 1988;  61 2407-2411
• 39 Salvadori B, Squicciarini P, Rovini D, Orefice S, Andreola S, Rilke F, Barletta L, Menard S, Colnaghi M I. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients.  Eur J Cancer. 1990;  26 865-867
• 40 Slade M J, Smith B M, Sinnett H D, Cross N C, Coombes R C. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer.  J Clin Oncol. 1999;  17 870-879
• 41 Untch M, Kahlert S, Funke I, Boettcher B, Konecny G, Nestle-Kraemling C, Bauernfeind I. Detection of cytokeratin (CK) 18 positive cells in the bone marrow (BM) of breast cancer patients - no prediction of bad outcome.  Proc ASCO. 1999;  18 693
• 42 Mathieu M C, Friedman S, Bosq J, Caillou B, Spielmann M, Travagli J P, Contesso G. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer.  Breast Cancer Res Treat. 1990;  15 21-26
• 43 Singletary S E, Larry L, Tucker S L, Spitzer G. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients.  J Surg Oncol. 1991;  47 32-36
• 44 Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S. Detection and clinical implications of early systemic tumor cell dissemination in breast cancer.  Clin Cancer Res. 2003;  9 6326-6334
• 45 Goldhirsch A, Glick J H, Gelber R D, Coates A S, Thurlimann B, Senn H J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.  Ann Oncol. 2005;  16 1569-1583
• 46 Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.  J Clin Oncol. 2000;  18 80-86
• 47 Janni W, Wiedswang G, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E F, Pantel K, Nesland J M, Friese K, Naume B. Persistence of disseminated tumor cells (DTC) in bone marrow (BM) during follow-up predicts increased risk for relapse - up-date of the pooled European data. Breast Cancer Res Treat 2006 70
• 48 Coombes R C, Berger U, Mansi J, Redding H, Powles T J, Neville A M, McKinna A, Nash A G, Gazet J C, Ford H T. et al . Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer.  NCI Monogr. 1986;  1 51-53
• 49 Kirk S J, Cooper G G, Hoper M, Watt P C, Roy A D, Odling-Smee W. The prognostic significance of marrow micrometastases in women with early breast cancer.  Eur J Surg Oncol. 1990;  16 481-485
• 50 Dearnaley D P, Ormerod M G, Sloane J P. Micrometastases in breast cancer: long-term follow-up of the first patient cohort.  Eur J Cancer. 1991;  27 236-239